Screener
Halozyme Therapeutics HALO Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The source filing: Halozyme Therapeutics’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:11 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001159036-26-000104
FAQ
- What is Halozyme Therapeutics's retained earnings?
- Halozyme Therapeutics (HALO) reported retained earnings of $151.26M in Q2 2026.
- How has Halozyme Therapeutics's retained earnings changed year-over-year?
- Halozyme Therapeutics's retained earnings decreased by 58.1% year-over-year, from $361.03M to $151.26M.
- What is the long-term trend for Halozyme Therapeutics's retained earnings?
- Over 5 years (2020 to 2025), Halozyme Therapeutics's retained earnings has grown at a -35.1% compound annual growth rate (CAGR), from -$474.59M to $54.79M.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.
Ask your AI about Halozyme Therapeutics's retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude